Alembic Pharma Q4 FY25: Sales up 17%, profit down 12%

What Alembic reported for Q4 FY25

Alembic Pharmaceuticals closed the March 2025 quarter with higher sales but weaker bottom-line growth on a year-on-year basis. Consolidated revenue from operations rose 17% to ₹1,770 crore for Q4 FY25. Total revenue for the quarter was reported at ₹1,783 crore. Net profit for the period was reported at ₹157 crore, reflecting a 12% to 12.1% year-on-year decline in various company updates. The quarter’s EBITDA increased 9% to ₹286 crore, indicating operating profit growth that lagged the pace of revenue. The company’s commentary pointed to stronger momentum outside the US and improved execution in India’s branded formulations.

Revenue growth, but profit pressure remained visible

While topline growth was strong in Q4 FY25, profitability did not track the same trajectory. Profit for the period before non-controlling interests declined 12.1% from ₹178 crore to ₹156 crore. In a separate disclosure around the same quarter, net profit was cited at ₹157 crore, broadly consistent with the decline referenced. Profit before tax (PBT) rose 5% to ₹192 crore in the quarter, suggesting the movement between PBT and PAT was influenced by below-the-line items. Group CFO R K Baheti also clarified that earlier write-offs on impaired assets had reduced taxation in previous years. EBITDA margin for the quarter was stated at 16% of total sales.

Other income increased sharply in the quarter

A notable feature of the quarter was the rise in income from other sources. Other income increased four-fold to ₹14.19 crore in Q4 FY25 from ₹3.6 crore in the comparable period. This lifted total revenue to ₹1,783 crore even as revenue from operations stood at ₹1,770 crore. Investors typically track other income because it can be volatile and not always linked to core operating performance. In this quarter, the primary focus still remained on operating revenue growth and segment-level momentum.

Segment snapshot: India, US, ex-US, animal health, and API

Alembic’s India branded business posted 8% year-on-year growth to ₹545 crore in the quarter, supported by specialty therapies, according to managing director Shaunak Amin. The company highlighted performance in therapeutic areas including gynaecology, anti-diabetic, ophthalmology, and dermatology. The anti-infective segment grew 7% and cough and cold grew 11% during the quarter, as per the same update. The US generics business grew 20% to ₹508 crore in Q4 FY25, supported by four product launches. Ex-US international generics grew 43% to ₹375 crore, aligning with management’s emphasis on growth across non-US markets.

Management commentary: growth outside the US and specialty push in India

Shaunak Amin said the Ex-US business delivered 43% growth across markets, while the India-branded business improved backed by specialty therapies. He also referenced resilience in the animal health business. Separately, the company said the animal health business grew 19% in the quarter. Management also stated it is emphasising greater engagement with healthcare professionals and building an expanding pipeline. These remarks were positioned as the operating drivers behind stronger performance in India and international markets.

Pipeline and launches: ANDA approvals and product additions

Alembic said it launched four new products during the quarter, taking year-to-date launches to 14. On the US regulatory side, the company added two new ANDA approvals, taking cumulative ANDA approvals to 220. These updates matter for investors tracking the sustainability of US generics performance, where approvals and launches translate into new revenue opportunities. The company’s quarterly narrative linked part of US growth to product launches during the period.

Full-year FY25 update: revenue growth and API challenges

On a full-year basis, Alembic’s FY25 revenue from operations was reported at ₹6,672 crore, up 7% versus the previous fiscal. The API segment posted 4% year-on-year growth in Q4 FY25 to ₹342 crore. However, the API business declined 9% for the full year to ₹1,133 crore. The company said it lost some large customers due to pricing competition and had started working on that, with an expectation that the API business would return to growth in FY26. This mix of quarterly growth but full-year decline highlights the uneven recovery in parts of the API franchise.

Geographic mix: how much comes from international markets

Alembic indicated that revenue from the US and other international markets accounts for around 50% of total sales, with growth of 20% and 43% respectively in the quarter. In a separate management update, the company also said the US contributes around 60% of its ₹1,200 crore international generics business. The company has been focusing on markets including the EU, Canada, Australia, and Latin American countries for the last two years, and management said this has yielded results. This context is important because it frames the 43% ex-US growth as part of a multi-year diversification effort.

Key numbers at a glance

Market impact: what investors typically track from this update

The quarter presents a split picture: strong revenue expansion but a decline in reported net profit. Investors are likely to focus on the durability of US growth (₹508 crore, +20%) alongside the sharp ex-US expansion (₹375 crore, +43%). India branded growth to ₹545 crore also remains a key anchor, given management’s emphasis on specialty therapies. The rise in other income to ₹14.19 crore adds to total revenue, but it is not a substitute for operating momentum. For longer-term tracking, the FY25 revenue from operations of ₹6,672 crore (+7%) provides the base, while the full-year API decline to ₹1,133 crore (-9%) flags a segment that needs recovery.

Why the quarter matters

Alembic’s Q4 FY25 results show that growth is broadening beyond a single geography, with management explicitly pointing to ex-US strength across markets. The updates on ANDA approvals (220 cumulative) and quarterly launches provide measurable indicators of execution in the generics pipeline. At the same time, the fall in net profit despite revenue growth underlines that earnings can remain sensitive to mix and below-the-line outcomes. The API commentary is also important because it acknowledges customer losses due to pricing competition and sets FY26 as a period to watch for a rebound.

Conclusion

Alembic Pharmaceuticals reported Q4 FY25 revenue from operations of ₹1,770 crore with EBITDA at ₹286 crore, while net profit declined to ₹157 crore despite higher sales. Management highlighted strong ex-US growth and improved India-branded performance backed by specialty therapies. The company also reported new launches and a higher cumulative ANDA approval count, while acknowledging a full-year decline in the API business. Subsequent quarters are expected to show how the company executes on plans to grow the US business and restore API growth in FY26.